Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 4,751 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.006 | -0.80% | 0.7451 | 07:33:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.7511 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 23 | 4,751 | - | 0.6711 - 5.95 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:45:15 | 12 | US$ 0.7451 | USD |
Spruce Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 30.53M | 40.71M | - | 10.09M | -47.92M | -1.18 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Spruce Biosciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.781 | 0.80 | 0.73 | 0.7590231 | 420,596 | -0.0359 | -4.60% |
| 1 Month | 0.6802 | 0.87 | 0.6802 | 0.7741353 | 451,007 | 0.0649 | 9.54% |
| 3 Months | 5.37 | 5.95 | 0.6711 | 1.16 | 1,398,458 | -4.62 | -86.12% |
| 6 Months | 1.32 | 5.95 | 0.6711 | 1.59 | 819,264 | -0.5749 | -43.55% |
| 1 Year | 2.52 | 5.95 | 0.6711 | 1.63 | 458,405 | -1.77 | -70.43% |
| 3 Years | 15.06 | 15.08 | 0.6711 | 3.29 | 655,306 | -14.31 | -95.05% |
| 5 Years | 17.00 | 35.60 | 0.6711 | 3.69 | 557,468 | -16.25 | -95.62% |
Spruce Biosciences Description
| Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |
